Evidence map›Paper›PMID 37724826›Full record

ArticleInternational journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience2023

Adaptive, behavioral, and cognitive outcomes in individuals with fragile X syndrome with varying autism severity.

Ramkumar Aishworiya, Ye Eun Tak, Matthew Dominic Ponzini, Hazel Maridith Barlahan Biag, Maria Jimena Salcedo-Arellano, Kyoungmi Kim, Flora Tassone, Andrea Schneider, Angela John Thurman, Leonard Abbeduto and 6 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Ramkumar AishworiyaMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.ORCID https://orcid.org/0000-0002-5749-1248
Ye Eun TakUniversity of California Davis School of Medicine, Sacramento, California, USA.
Matthew Dominic PonziniMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.
Hazel Maridith Barlahan BiagMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.
Maria Jimena Salcedo-ArellanoMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.
Kyoungmi KimMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.
Flora TassoneMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.
Andrea SchneiderMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.
Angela John ThurmanMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.
Leonard AbbedutoMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.
David HesslMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.
Jamie Leah RandolUniversity of California Davis School of Medicine, Sacramento, California, USA.
Francois V BolducDivision of Pediatric Neurology, Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
Sarah LippeDépartement de Psychologie, Université de Montréal, Montréal, Québec, Canada.
Paul HagermanMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.
Randi HagermanMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Davis, California, USA.
University of California, Davis · USCentre Hospitalier Universitaire Sainte-Justine · CANational University of Singapore · SGUniversity of Alberta · CA

Funding

Research Project: Pathologic Significance of Maternal AutoantibodiesP50HD103526 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEONARD J. ABBEDUTO, Melissa Dawn Bauman · 2020 to 2026
$9.7M
NICHD NIH HHS P50 HD103526
6 · The paper itself

Abstract

This study aimed to determine the association between severity of autism spectrum disorder (ASD) and cognitive, behavioral, and molecular measures in individuals with fragile X syndrome (FXS). Study inclusion criteria included individuals with FXS and (1) age 6-40 years, (2) full-scale IQ < 84, and (3) language ≥3-word phrases. ASD symptom severity was determined by Autism Diagnostic Observation Schedule-2 (ADOS-2). Other measures identified non-verbal IQ, adaptive skills, and aberrant behaviors. Molecular measures included blood FMR1 and CYFIP1 mRNA levels, FMRP and MMP9 levels. Analysis of variance (ANOVA) and Spearman's correlations were used to compare ASD severity groups. Data from 54 individuals was included with no/mild (N = 7), moderate (N = 18), and severe (N = 29) ASD. Individuals with high ASD severity had lower adaptive behavior scores (47.48 ± 17.49) than the no/mild group (69.00 ± 20.45, p = 0.0366); they also had more challenging behaviors, lethargy, and stereotypic behaviors. CYFIP1 mRNA expression levels positively correlated with the ADOS-2 comparison score(r

Indexed as

Autism Spectrum DisorderAutistic DisorderFragile X SyndromeAdolescentAdultChildCognitionFragile X Messenger Ribonucleoprotein 1HumansRNA, MessengerYoung AdultFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1RNA, MessengerautismCYFIP1 mRNAFMRPfragile X syndromeMMP9

Identifiers

PMID37724826
PMCPMC10868665
OpenAlexW4386845181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.